Drug Discovery World

AUGUST 16, 2023

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The presence of these biomarkers could be used to accelerate the development of more personalised treatments for triple negative breast cancers.

Genetics 52

Genetics Gene Hormones RNA 52

Olympian Clinical Research

NOVEMBER 6, 2023

While the exact cause is unknown, factors like genetics, inflammation, and hormones play a role. Here are some common triggers of HS: Hormonal Changes: Many individuals with HS report flare-ups during periods of hormonal change, such as menstruation, pregnancy, or menopause.

Hormones 52

Hormones Doctors Doctor Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

Dr. Lisa Forbes — his doctor and co-author of a letter describing his case in the Oct. This patient had a genetic mutation that ruxolitinib is known to work on. Forbes said it’s not clear if other people with type 1 diabetes also have this specific genetic mutation. WEDNESDAY, Oct.

Insulin 52

Insulin Genetics Doctors Doctor 52

Delveinsight

JANUARY 13, 2021

An Individual’s metabolic activity, genetics, environmental factors, behavior, and hormones can supposedly cause overweight and obesity. Apart from calorie and physical activity, some of the genetic and social factors also influence the prevalence of obesity. What causes obesity? Obesity Pandemic.

Hormones 52

Hormones Gene Genetics Production 52

The Pharma Data

JUNE 18, 2021

IMBRUVICA is the most comprehensively studied BTK inhibitor, with more than 150 ongoing clinical trials. There are approximately 30 ongoing company-sponsored trials, 14 of which are in Phase 3, and more than 100 investigator-sponsored trials and external collaborations that are active around the world. 5 Burger JA et al.

Medicine 40

Medicine Production FDA Approval Trials 40

The Pharma Data

JUNE 18, 2021

IMBRUVICA is the most comprehensively studied BTK inhibitor, with more than 150 ongoing clinical trials. There are approximately 30 ongoing company-sponsored trials, 14 of which are in Phase 3, and more than 100 investigator-sponsored trials and external collaborations that are active around the world. November 2020.

Medicine 52

Medicine Production FDA Approval Trials 52

The Pharma Data

JUNE 18, 2021

IMBRUVICA ® is the most comprehensively studied BTK inhibitor, with more than 150 ongoing clinical trials. There are approximately 30 ongoing company-sponsored trials, 14 of which are in Phase 3, and more than 100 investigator-sponsored trials and external collaborations that are active around the world. November 2020.

FDA Approval 40

FDA Approval Medicine Development Trials 40